ZGNX Share Price

Open 14.95 Change Price %
High 15.15 1 Day 0.00 0.00
Low 14.84 1 Week 0.30 2.04
Close 15.00 1 Month 2.35 18.58
Volume 1008260 1 Year 6.91 85.41
52 Week High 15.40
52 Week Low 7.33
ZGNX Important Levels
Resistance 2 15.29
Resistance 1 15.17
Pivot 15.00
Support 1 14.83
Support 2 14.71
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Zogenix, Inc. (NASDAQ: ZGNX)

ZGNX Technical Analysis 5
As on 23rd Jun 2017 ZGNX Share Price closed @ 15.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 10.77 & Strong Buy for SHORT-TERM with Stoploss of 12.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
ZGNX Target for June
1st Target up-side 14.48
2nd Target up-side 15.73
3rd Target up-side 16.98
1st Target down-side 10.92
2nd Target down-side 9.67
3rd Target down-side 8.42
ZGNX Other Details
Segment EQ
Market Capital 232515696.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.zogenix.com
ZGNX Address
ZGNX
12400 High Bluff Drive
Suite 650
San Diego, CA 92130
United States
Phone: 858-259-1165
Fax: 858-259-1166
ZGNX Latest News
Zogenix Inc. (ZGNX) Breaks into New 52-Week High on June 22 Session   Equities.com   - 23rd Jun 17
Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of ...   GlobeNewswire (press release)   - 22nd Jun 17
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual ...   GlobeNewswire (press release)   - 22nd May 17
Zogenix: Buy The Run-Up Into Third Quarter Data   Seeking Alpha   - 15th May 17
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet ...   GlobeNewswire (press release)   - 27th Apr 17
Zogenix Is On The Precipice Of Substantial Growth - Part 2   Seeking Alpha   - 08th Mar 17
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in ...   GlobeNewswire (press release)   - 01st Mar 17
Zogenix Is On The Precipice Of Substantial Growth   Seeking Alpha   - 24th Feb 17
Zogenix Announces Issuance of US Patent for ZX008 in Dravet Syndrome   GlobeNewswire (press release)   - 30th Jan 17
Zogenix Announces CFO Transition   GlobeNewswire (press release)   - 06th Jan 17
Interactive Technical Analysis Chart Zogenix, Inc. ( ZGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Zogenix, Inc.
ZGNX Business Profile
Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company�s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).